Satralizumab-话题@MedSci

#Satralizumab#

8篇内容 | 683人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1674272, encodeId=359316e427229, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, objectTitle=Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验, objectType=article, longId=204612, objectId=b76e204612db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b76e204612db, replyNumber=0, likeNumber=23, createdTime=2021-03-30, rootId=0, userName=zblhy, userId=7ef626951425, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b76e204612db, moduleTitle=Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b76e204612db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674270, encodeId=001016e4270e8, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, objectTitle=2020EAN大会速递丨青少年NMOSD患者Satralizumab给药方案：与成年患者一致, objectType=article, longId=195606, objectId=b86a1956069e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86a1956069e, replyNumber=0, likeNumber=33, createdTime=2021-03-26, rootId=0, userName=zblhy, userId=7ef626951425, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86a1956069e, moduleTitle=2020EAN大会速递丨青少年NMOSD患者Satralizumab给药方案：与成年患者一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b86a1956069e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674271, encodeId=ffdd16e4271fb, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, objectTitle=2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案, objectType=article, longId=195607, objectId=c7a119560ea0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a119560ea0, replyNumber=0, likeNumber=49, createdTime=2020-10-30, rootId=0, userName=zblhy, userId=7ef626951425, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a119560ea0, moduleTitle=2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a119560ea0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674269, encodeId=e37616e426922, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, objectTitle=2020EAN大会速递丨SAkura研究：Satralizumab治疗前沿 MedSci梅斯 6天前, objectType=article, longId=195297, objectId=482d19529e0f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482d19529e0f, replyNumber=0, likeNumber=18, createdTime=2020-11-16, rootId=0, userName=zblhy, userId=7ef626951425, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482d19529e0f, moduleTitle=2020EAN大会速递丨SAkura研究：Satralizumab治疗前沿 MedSci梅斯 6天前, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482d19529e0f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674268, encodeId=325416e426871, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, objectTitle=Lancet Neurology：Satralizumab治疗视神经脊髓炎谱系障碍（NMOSD），安全有效, objectType=article, longId=193031, objectId=f1fd19303162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1fd19303162, replyNumber=0, likeNumber=36, createdTime=2020-04-29, rootId=0, userName=zblhy, userId=7ef626951425, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1fd19303162, moduleTitle=Lancet Neurology：Satralizumab治疗视神经脊髓炎谱系障碍（NMOSD），安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1fd19303162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674267, encodeId=d8d016e426788, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, objectTitle=罗氏的白细胞介素6受体单抗Satralizumab治疗视神经脊髓炎谱系障碍的临床试验成功, objectType=article, longId=184086, objectId=1b3518408695, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b3518408695, replyNumber=0, likeNumber=33, createdTime=2020-07-13, rootId=0, userName=zblhy, userId=7ef626951425, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b3518408695, moduleTitle=罗氏的白细胞介素6受体单抗Satralizumab治疗视神经脊髓炎谱系障碍的临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b3518408695)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674265, encodeId=1e6416e426524, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, objectTitle=Satralizumab获得日本孤儿药物认定，用以治疗视网膜神经脊髓炎和神经脊髓炎视觉障碍, objectType=article, longId=179454, objectId=c7ad1e945427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ad1e945427, replyNumber=0, likeNumber=32, createdTime=2020-04-20, rootId=0, userName=zblhy, userId=7ef626951425, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ad1e945427, moduleTitle=Satralizumab获得日本孤儿药物认定，用以治疗视网膜神经脊髓炎和神经脊髓炎视觉障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ad1e945427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674266, encodeId=764416e426652, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, objectTitle=NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果, objectType=article, longId=183902, objectId=8908183902b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8908183902b8, replyNumber=0, likeNumber=32, createdTime=2020-01-11, rootId=0, userName=zblhy, userId=7ef626951425, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8908183902b8, moduleTitle=NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8908183902b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Satralizumab

2020-05-29

zblhy (审核中...)

前往app查看评论内容

#Satralizumab#

Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验

2021-03-30

zblhy (审核中...)

前往app查看评论内容

#Satralizumab#

2020EAN大会速递丨青少年NMOSD患者Satralizumab给药方案：与成年患者一致

2021-03-26

zblhy (审核中...)

前往app查看评论内容

#Satralizumab#

2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案

2020-10-30

zblhy (审核中...)

前往app查看评论内容

#Satralizumab#

2020EAN大会速递丨SAkura研究：Satralizumab治疗前沿 MedSci梅斯 6天前

2020-11-16

zblhy (审核中...)

前往app查看评论内容

#Satralizumab#

Lancet Neurology：Satralizumab治疗视神经脊髓炎谱系障碍（NMOSD），安全有效

2020-04-29

zblhy (审核中...)

前往app查看评论内容

#Satralizumab#

罗氏的白细胞介素6受体单抗Satralizumab治疗视神经脊髓炎谱系障碍的临床试验成功

2020-07-13

zblhy (审核中...)

前往app查看评论内容

#Satralizumab#

Satralizumab获得日本孤儿药物认定，用以治疗视网膜神经脊髓炎和神经脊髓炎视觉障碍

2020-04-20

zblhy (审核中...)

前往app查看评论内容

#Satralizumab#

NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果

2020-01-11

科室
- - 订阅+
  - 更多科室
工具
服务